BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar
- Conditions
- Hepatitis C
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 182
- Registration Number
- NCT03205618
- Locations
- 🇸🇦
Local Institution, Riyadh-11211, Saudi Arabia
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
- Conditions
- Advanced Cancer
- Interventions
- Biological: LirilumabBiological: NivolumabBiological: Ipilimumab
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT03203876
- Locations
- 🇯🇵
Local Institution, Kobe-shi, Hyogo, Japan
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
- Conditions
- Melanoma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 650
- Registration Number
- NCT03199846
- Locations
- 🇺🇸
Local Institution, Morristown, New Jersey, United States
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
- Conditions
- Lymphoma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 95
- Registration Number
- NCT03200977
- Locations
- 🇺🇸
Local Institution - 0001, Lawrenceville, New Jersey, United States
🇺🇸Center for International Blood and Marrow Transplant Research, Milwaukee, Wisconsin, United States
A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 63
- Registration Number
- NCT03198182
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 691
- Registration Number
- NCT03197779
- Locations
- 🇺🇸
Wcct Global, Llc, Cypress, California, United States
🇺🇸California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸Parexel International - Baltimore Epcu, Baltimore, Maryland, United States
A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT03198013
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject
- Conditions
- Immunoscience
- Interventions
- Drug: PrenisoloneDrug: Placebo
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT03196557
- Locations
- 🇺🇸
Ppd Development, Austin, Texas, United States
🇺🇸Local Institution, Austin, Texas, United States
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT03195478
- Locations
- 🇨🇳
Local Institution - 0001, Beijing, Beijing, China
🇨🇳Local Institution - 0012, Guangzhou, Guangdong, China
🇨🇳Local Institution - 0020, XiAn, Shan1xi, China
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
- Conditions
- Lung CancerNon-Small Cell Lung Cancer
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT03195491
- Locations
- 🇹🇭
Local Institution, Khon Kaen, Thailand
🇨🇳Local Institution - 0017, Changsha, Hunan, China